

September 4, 2025



# Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Encinitas, California--(Newsfile Corp. - September 4, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its Chief Financial Officer, Melissa Tosca, CPA, will showcase the Company's pipeline of therapies targeting inherited and inflammatory retinal diseases at the H.C. Wainwright 27<sup>th</sup> Annual Global Investment Conference.

## Presentation Details

Date: Friday, September 5th, 2025

Time: 7:00 am Eastern Daylight Time

Link: <https://ir.kiorapharma.com/news-events/events>

The replay will be available on-demand for 90 days on Kiora's investor relations website.

## **About Kiora Pharmaceuticals**

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

In addition to news releases and SEC filings, we expect to post information on our website, [www.kiorapharma.com](http://www.kiorapharma.com), and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.

## **Contact:**

[investors@kiorapharma.com](mailto:investors@kiorapharma.com)



To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/265030>

SOURCE Kiora Pharmaceuticals, Inc.